Company news

Passage Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

January 3, 2021

Passage Bio Announces Gene Therapy Manufacturing Research and Development Site

December 15, 2020

Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis

December 9, 2020

Passage Bio Teams with Catalent to Start CGMP Manufacturing for Lead Gene Therapy Products

December 6, 2020

Passage Bio Reports Third Quarter 2020 Financial Results and Recent Business Highlights

November 9, 2020

Passage Bio and Invitae Announce Collaboration to Facilitate Genetic Testing to Support Early Diagnosis and Greater Awareness of Clinical Trials for Patients with GM1

November 8, 2020

Passage Bio to Report Third Quarter 2020 Financial Results on November 10, 2020

November 3, 2020

Passage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease

October 27, 2020

Passage Bio’s PBGM01 Receives Orphan Drug Designation from EMA for Treatment of GM1 Gangliosidosis

October 25, 2020

Passage Bio Announces Publication of Preclinical Data That Show Single Injection of Optimized AAV Vector into Cerebral Spinal Fluid Corrects Neurological Disease, Supporting Advancement of PBGM01 into Clinic

October 12, 2020

Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program

September 16, 2020

Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights

August 12, 2020

Passage Bio to Report Second Quarter 2020 Financial Results on August 13, 2020

August 6, 2020

Passage Bio Receives Rare Pediatric Disease Designation for PBGM01 for Patients with GM1 Gangliosidosis

May 20, 2020

Passage Bio Announces Presentation of Data from Animal Models of Krabbe Disease at the American Society of Gene & Cell Therapy (ASGCT) 23rd Annual Meeting

May 11, 2020

Passage Bio Reports First Quarter 2020 Financial Results and Recent Business Highlights

May 10, 2020

Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania

May 6, 2020

Passage Bio to Report First Quarter 2020 Financial Results on May 11, 2020

May 3, 2020

FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis

April 20, 2020

Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares

March 8, 2020

Passage Bio Appoints Athena Countouriotis to Board of Directors

March 4, 2020

Passage Bio Announces Pricing of Initial Public Offering

February 26, 2020

← Newer news releases

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 39 decks. Every deck is listed under its year.